RT Book, Section
A1 Patel, Sameer H.
A1 Passot, Guillaume
A1 Vauthey, Jean-Nicolas
A2 Zinner, Michael J.
A2 Ashley, Stanley W.
A2 Hines, O. Joe
SR Print(0)
ID 1160044288
T1 Malignant Liver Neoplasms
T2 Maingot's Abdominal Operations, 13e
YR 2019
FD 2019
PB McGraw-Hill Education
PP New York, NY
SN 9780071843072
LK accesssurgery.mhmedical.com/content.aspx?aid=1160044288
RD 2024/04/19
AB In  2018,  primary  liver  tumors  will  be  diagnosed  in  approximately  42,220  new  patients  in  the  United  States,  and  approximately  30,200  individuals  will  die  from  this  disease.1  Worldwide,  primary  liver  tumors  remain  the  second  leading  cause  of  death  from  cancer  in  males  and  the  sixth  leading  cause  of  death  from  cancer  in  females.2  Malignant  lesions  can  arise  from  any  of  the  various  cell  types  that  comprise  the  organ,  which  include  hepatocytes,  endothelial  cells,  and  the  cells  of  the  intrahepatic  bile  ducts.  The  2  most  common  hepatic  neoplasms  are  hepatocellular  carcinoma  (HCC),  which  accounts  for  more  than  75%  of  primary  liver  tumors,  and  intrahepatic  cholangiocarcinoma  (ICC),  which  accounts  for  10%  to  15%.  The  remaining  primary  hepatic  neoplasms  are  hepatic  angiosarcoma,  epithelioid  hemangioendothelioma,  and  hepatic  lymphoma.  The  focus  of  this  chapter  will  be  on  HCC  and  ICC.